宝济药业-B正式获纳港股通开启价值重估新航道

智通财经03-09

宝济药业-B(02659)发布公告，根据《上海证券交易所沪港通业务实施办法》及《深圳证券交易所深港通业务实施办法》相关规定，公司发行并于香港联合交易所有限公司上市的股份(H股)将获纳入沪港通及深港通(统称“港股通”)项下的合资格证券，自2026年3月9日起生效。此举标志着公司正式进入内地投资者视野，有望凭借资本准入与价值重估迎来双重契机。　　据悉，港股通作为连接内地与香港资本市场的重要通道，纳入...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618618030?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-09 09:36","share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","id":"2618618030","market":"sg","top_or_hot":-1,"title":"宝济药业-B正式获纳港股通 开启价值重估新航道","media":"智通财经","content":"<div>\n<p>宝济药业-B(02659)发布公告，根据《上海证券交易所沪港通业务实施办法》及《深圳证券交易所深港通业务实施办法》相关规定，公司发行并于香港联合交易所有限公司上市的股份(H股)将获纳入沪港通及深港通(统称“港股通”)项下的合资格证券，自2026年3月9日起生效。此举标志着公司正式进入内地投资者视野，有望凭借资本准入与价值重估迎来双重契机。　　据悉，港股通作为连接内地与香港资本市场的重要通道，纳入...</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20260309/c675151071.shtml\">网页链接</a>\n\n</div>\n","source":"tonghuashun","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>宝济药业-B正式获纳港股通 开启价值重估新航道</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n宝济药业-B正式获纳港股通 开启价值重估新航道\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 09:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://stock.10jqka.com.cn/hks/20260309/c675151071.shtml><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>宝济药业-B(02659)发布公告，根据《上海证券交易所沪港通业务实施办法》及《深圳证券交易所深港通业务实施办法》相关规定，公司发行并于香港联合交易所有限公司上市的股份(H股)将获纳入沪港通及深港通(统称“港股通”)项下的合资格证券，自2026年3月9日起生效。此举标志着公司正式进入内地投资者视野，有望凭借资本准入与价值重估迎来双重契机。　　据悉，港股通作为连接内地与香港资本市场的重要通道，纳入...</p>\n\n<a href=\"http://stock.10jqka.com.cn/hks/20260309/c675151071.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0070","symbol_name":"员工持股","start_time":0,"source_url":"http://stock.10jqka.com.cn/hks/20260309/c675151071.shtml","article_id":"2618618030","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618618030","pubTimestamp":1773020160,"columns":[],"sourceInfo":{"source_id":"tonghuashun","name":"同花顺"},"weMediaInfo":null,"summary":"宝济药业-B(02659)发布公告，根据《上海证券交易所沪港通业务实施办法》及《深圳证券交易所深港通业务实施办法》相关规定，公司发行并于香港联合交易所有限公司上市的股份(H股)将获纳入沪港 ...","collect":0,"end_time":0,"defaultTopTitle":"10jqka.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300009":"安科生物","BK0070":"员工持股","BK0042":"基因检测","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"Baoji Pharmaceutical-B officially received Hong Kong Stock Connect, opening a new channel for value revaluation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300009":1},"content_text":"宝济药业-B(02659)发布公告，根据《上海证券交易所沪港通业务实施办法》及《深圳证券交易所深港通业务实施办法》相关规定，公司发行并于香港联合交易所有限公司上市的股份(H股)将获纳入沪港通及深港通(统称“港股通”)项下的合资格证券，自2026年3月9日起生效。此举标志着公司正式进入内地投资者视野，有望凭借资本准入与价值重估迎来双重契机。　　据悉，港股通作为连接内地与香港资本市场的重要通道，纳入标的需满足市值、流动性等多重标准。对于宝济药业而言，纳入港股通将极大提升其股票的市场流动性。当南下资金增量与公司“创新研发+生物制造”的技术战略深度作用，有利于稳固公司在医疗健康产业的成长逻辑与发展前景，进一步向资本市场证明其作为新一代平台型Biopharma的结构性价值。　　宝济药业在商业转化层面有望迎来重大催化，多款核心产品今年或将带来显著收入。西牛证券指出：KJ017(重组人透明质酸酶)有望于2026年获得NDA批准，目前重组人透明质酸酶并无作为单药疗法在中国市场销售，一旦上市将可能释放巨大的商业增量，或将加速推动公司商业化进程；公司自主开发的长效重组人促卵泡激素(FSH-CTP)注射剂晟诺娃(SJ02)已获批上市，并与安科生物（300009）(300009.SZ)达成大中华区独家销售协议，成功实现商业化落地。　　长期来看，依托领先的底盘细胞构建能力、稳定的商业化生产体系及经验丰富的研发团队，宝济药业在商业化转化路径上具备强劲动能。随着核心产品管线持续推进，公司有望实现资本价值与业绩的双重增长，持续彰显其投资价值。 \n关注同花顺财经（ths518），获取更多机会","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618618030","isCrawlerRequest":true}

宝济药业-B正式获纳港股通 开启价值重估新航道

精彩评论

宝济药业-B正式获纳港股通开启价值重估新航道